Achilles Therapeutics presents encouraging Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma

Achilles Therapeutics, a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumours, presented a Phase I/IIa update on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma, at the ESMO Immuno-Oncology Congress 2022.ESMO.

Achilles brings together world-leading expertise in tumour sequencing and immune response to develop a new type of personalised treatment for cancer patients. Achilles Therapeutics was founded on CRUK-funded research carried out by Professors Karl Peggs, Mark Lowdell, and Sergio Quezada from UCL, and Charles Swanton from UCL and the Francis Crick Institute. Since its creation in 2016, Achilles has made rapid progress in developing treatments which involve finding and amplifying a patient’s own T cells to fight cancer.

Read the full story from Achilles.